ex scientia和Sunovion公司签订精神病药物研发协议

药物研发公司 ex scientia 与Sunovion 制药签订一项4800万美元的协议，合作研发和优化精神病治疗药物的新方法。Sunovion将拥有协议中规定的全球制造和销售权，而ex scientia则持有药物研发的技术权。Ex scientia采用的是一种系统的多聚药理学(polypharmacology)研发方法进行多靶点药物分子的设计和制造。

该项目将致力于药物复合物设计的新方法的研发——“表征型新药研发(Phenotypic DrugDiscovery)”。科研人员将利用成熟的与疾病相关的表征型药物筛选模型，通过一个安全保密的门户网站，对全球各地的大学和生物技术实验室合成的化合物的生物表征型进行分析和评估。研究人员可以在保密的情况下，通过自动化的Phenotypic DrugDiscovery界面提交其化合物结构，由计算机系统通过专有的运算法则对化合物的类药性和结构新颖性进行初步计算评估。如果化合物结构符合某特定标准，研究人员将获邀提交一份物理样本进行生物测试。本阶段知识产权归提交人员和/或机构所有。Phenotypic DrugDiscovery的目标并非提倡随意提交大量化合物，而是鼓励对具有新颖的结构多样性的分子进行全面的生物表征型测试。

ex scientia的创始人兼CEO Andrew Hopkins在声明中表示，该合作显示了将多聚药理学的理念应用到疾病药物研发的巨大潜力，并期望该项目的研发成果能在未来与其他大的制药公司建立战略合作关系，共同促进精神病药物的研究。（转化医学网360zhyx.com）

原文：

ex scientia, SunovionInk Psychiatric Drug Discovery Deal

In a deal said to be worth $4.8 million, drug discovery company ex scientia is teaming up withSunovion Pharmaceuticals to discover and optimize novel medicines for psychiatric disorders. Sunovion has paid ex scientia $1 million up front and is picking up exclusive worldwide rights to compounds resulting from the agreement. ex scientia is retaining the exclusive rights to its technology, which it describes as a systematic algorithmic discovery platform to design molecules to a tailored polypharmacology or "bispecific" target profile.

The firms will focus on developing novel approaches to compound design by analyzing data arising from phenotypic drug discovery. ex scientia says the pact combines the power of phenotypicscreening with its technology for the rational design ofpolypharmacologydrugs and will build upon ex scientia's delivery of bispecific compounds that combine activities at the GPCR and ion channel target families.

"This partnership establishes our design platform as a method of choice for data-driven phenotypic drug discovery," ex scientia's founder and CEO Andrew Hopkins said in a statement. "The agreement shows the power of applying a polypharmacology philosophy to challenging disease areas and our commitment to building strategic partnerships with major pharmaceutical companies to deliver novel medicines."